Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomized, double dummy, double blind, multi-center multinational trial comparing the efficacy and safety of moxifloxacin 400 mg PO QD 24 hours for 14 days to that of levofloxacin 500 mg PO QD 24 hours plus metronidazole 500 mg BID for 14 days in subjects with an uncomplicated pelvic inflammatory disease. Moxifloxacin, metronidazole, and levofloxacin in Asia (MONALISA study).

Next Previous
Trial Profile

A prospective, randomized, double dummy, double blind, multi-center multinational trial comparing the efficacy and safety of moxifloxacin 400 mg PO QD 24 hours for 14 days to that of levofloxacin 500 mg PO QD 24 hours plus metronidazole 500 mg BID for 14 days in subjects with an uncomplicated pelvic inflammatory disease. Moxifloxacin, metronidazole, and levofloxacin in Asia (MONALISA study).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Moxifloxacin (Primary) ; Levofloxacin; Metronidazole
  • Indications Bacterial infections; Gynaecological infections; Pelvic inflammatory disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms MONALISA
  • Sponsors Bayer HealthCare

Most Recent Events

  • 10 Oct 2009 Results reported at FIGO World Congress.
  • 10 Oct 2008 Bayer HealthCare reported as trial affiliate by ClinicalTrials.gov.
  • 07 Oct 2008 Actual number of patients (460) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top